Oxford Biomedica to manufacture vectors for Boehringer Ingelheim

By The Science Advisory Board staff writers

April 6, 2021 -- Oxford Biomedica has signed a three-year deal to manufacture and supply various types of viral vectors to Boehringer Ingelheim.

Under the terms of the development and supply agreement, Oxford Biomedica said it intends to manufacture good manufacturing practice (GMP) batches for Boehringer Ingelheim to support the development of viral vectors. The agreement also allows for Oxford Biomedica to manufacture and supply viral vectors in the future, according to the company.

Oxford Biomedica and its subsidiaries have built LentiVector, a lentiviral vector delivery platform that they use to develop in vivo and ex vivo products both internally and with partners.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.